PRESS RELEASE

Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

SAN DIEGO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, Obalon’s President and Chief Financial Officer, and Bob MacDonald, the Company’s Chief Retail Officer will present a corporate overview at the Canaccord Genuity 39th Annual Growth Conference taking place August 7-8, 2019 in Boston.                                                                                  

Presentation Details:

Date and Time: Thursday, August 8, 2019, 9:00am ET
Location: InterContinental Hotel, Boston, MA
A webcast of the live presentation will be accessible at http://wsw.com/webcast/canaccord35/obln/ and will be archived for 90 days following the event. 

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit http://www.obalon.com/.

For Obalon Therapeutics, Inc.

Investor Contact:
William Plovanic
President and Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com

Obalon_Logo_Teal_2c.jpg

Source: Obalon Therapeutics, Inc.

IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling